Literature DB >> 6616956

Effect on the human complement system of the major non-steroidal anti-inflammatory drugs: aspirin, indomethacin, phenylbutazone, oxyphenbutazone and sulindac.

J O Minta, M B Urowitz, H A Smythe, D E Isenman.   

Abstract

The possibility that the major non-steroidal anti-inflammatory drugs may inhibit the complement system and thus ameliorate the acute pathological changes induced by immune complexes was investigated. Treatment of fresh human serum with indomethacin (IDM), sulindac (Su), phenylbutazone (Ph) and oxyphenbutazone (OPh) inhibited both the classical and alternative complement (C) pathway activities in a dose-dependent fashion with a 50% inhibition dose of 4.65, 1.0, 1.65 and 1.3 mg/ml respectively. Aspirin, on the other hand, had a comparatively weak anti-complementary activity. Su, Ph and OPh were shown to form complexes with C5, thereby inhibiting the interaction between C3b and C5 and the cleavage of the latter into phlogistic fragments.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6616956      PMCID: PMC1535661     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Fifth component of human complement: purification from plasma and polypeptide chain structure.

Authors:  B F Tack; S C Morris; J W Prahl
Journal:  Biochemistry       Date:  1979-04-17       Impact factor: 3.162

2.  Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane.

Authors:  G Fairbanks; T L Steck; D F Wallach
Journal:  Biochemistry       Date:  1971-06-22       Impact factor: 3.162

3.  A neutrophil chemotactic factor from human C'5.

Authors:  P A Ward; L J Newman
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

Review 4.  Release of inflammatory mediators from stimulated neutrophils.

Authors:  G Weissmann; J E Smolen; H M Korchak
Journal:  N Engl J Med       Date:  1980-07-03       Impact factor: 91.245

5.  Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation.

Authors:  W Vogt; G Schmidt; B Hinsch
Journal:  Immunology       Date:  1979-01       Impact factor: 7.397

6.  Different affinities of mono-, di- and tri-DNP- ribonuclease A for anti-DNP antibody.

Authors:  S Taniuchi; T Honjoh; K Tamoto; T Nakamura; J Koyama
Journal:  Mol Immunol       Date:  1981-04       Impact factor: 4.407

7.  The effects of mild reduction on the structure and function of C3.

Authors:  D E Isenman; J S Sundsmo; N R Cooper
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

8.  The reaction mechanism of human C5 in immune hemolysis.

Authors:  N R Cooper; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

9.  Selective deficiency of the fourth component of complement in a patient with systemic lupus erythematosus (SLE): immunochemical and biological studies.

Authors:  J O Minta; M B Urowitz; D D Gladman; T Irizawa; W D Biggar
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

10.  Effect of aspirin on the complement system in vitro.

Authors:  G M Hänsch; V Voigtländer; U Rother
Journal:  Int Arch Allergy Appl Immunol       Date:  1980
View more
  2 in total

1.  Modulation of mRNA expression and secretion of C1q in mouse macrophages by anti-inflammatory drugs and cAMP: evidence for the partial involvement of a pathway that includes cyclooxygenase, prostaglandin E2 and adenylate cyclase.

Authors:  P K Trinder; D Faust; F Petry; M Loos
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

2.  Complement Activation in Association with Markers of Neutrophil Extracellular Traps and Acute Myocardial Infarction in Stable Coronary Artery Disease.

Authors:  Karsten E Kluge; Miriam S Langseth; Trine B Opstad; Alf Å Pettersen; Harald Arnesen; Theis Tønnessen; Ingebjørg Seljeflot; Ragnhild Helseth
Journal:  Mediators Inflamm       Date:  2020-03-26       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.